Background: Since its introduction in 1988, recombinant human erythropoietin (epoetin)
States. Herein, we report on the long-term outcome of these individuals.
Methods: For 170 chronic kidney disease patients who developed epoetin-associated PRCA and had three months or more follow-up information available, case reports from the Food and Drug Administration and epoetin manufacturers were reviewed for information on clinical characteristics of the patients, immunosuppressive treatments, epoetin responsiveness, and hematologic recovery.
Results: Overall, 64% of the PRCA patients received immunosuppressive therapy, including 19 who also underwent a renal transplant. Thirty-seven percent experienced a hematologic recovery, with higher hematologic recovery rates among PRCA patients who received immunosuppressive therapy (57% vs. 2%, p<0.0001). Among 34 patients who received epoetin after the onset of PRCA, 56% regained epoetin responsiveness. The highest rates of epoetin responsiveness were observed among persons whose antierythropoietin antibodies were undetectable when epoetin was administered (89%).
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From Conclusions: Among chronic kidney disease patients with epoetin-associated PRCA, epoetin discontinuation and immunosuppressive therapy or renal transplantation is necessary for hematologic recovery. Re-initiation of epoetin therapy among individuals could be considered if anti-erythropoietin antibodies are undetectable.
INTRODUCTION
Epoetin-associated pure red cell aplasia (PRCA) is a recently identified syndrome characterized by anemia, low reticulocyte count, absence of erythroblasts on bone marrow examination, resistance to epoetin therapy, and neutralizing antibodies against erythropoietin (Table 1) . [1] [2] [3] Antibodies obtained from individuals with epoetin-associated PRCA are cross-reactive with all forms of both endogenous and exogenous erythropoietin. From 1988 to 1998, three chronic kidney disease patients were reported to have developed this syndrome following long-term treatment with recombinant human erythropoietin. [4] [5] [6] In the mid-1990s, a shift from intravenous to subcutaneous epoetin administration occurred in many countries due to clinical and economic considerations. optimal discriminant analysis. 15 Effects with generalized p<0.05 were considered statistically significant.
RESULTS
Of 191 patients with epoetin-associated PRCA identified worldwide, follow-up information of three months or greater was available for 170 (89% Of 34 patients who received epoetin after the onset of PRCA, 56% recovered epoetin responsiveness ( Table 2 ). The highest rate of epoetin responsiveness was noted among those who had no detectable anti-erythropoietin antibodies at the time of epoetin administration (89%). Of fourteen PRCA patients who were receiving immunosuppressive therapy and had detectable antibody levels by enzyme-linked immunosorbent assay (ELISA) or radioimmunoprecipitation assay (RIPA) at the time of rechallenge, eight (57%) recovered epoetin responsiveness. However, results of antierythropoietin antibody neutralizing assays were not reported for any of these eight individuals. Three of the eleven PRCA patients who had detectable antibody levels and did not receive immunosuppression responded to epoetin rechallenge (27% response rate). In each of these three cases, antibodies confirming the diagnosis of epoetinassociated PRCA were detected using the RIPA method. No neutralizing activity was detected in one patient, a repeat RIPA was borderline positive in the second patient, and antibodies were not re-evaluated prior to death in the third patient. Of the 15 PRCA patients who did not respond to epoetin retreatment, three died, five received additional immunosuppressive therapy and ultimately achieved a hematologic recovery, two remained heavily transfusion dependent, and long-term clinical follow-up was unavailable for the remaining five individuals.
DISCUSSION
We have reported on the treatment and long-term follow-up of patients worldwide with epoetin-associated PRCA, 86% of whom had received Eprex 
cyclosporine. Doses and schedules commonly used were similar to those that had been used for individuals with other immune-mediated cytopenias (Table 3) . As no randomized clinical trials of alternative immunosuppressive therapies can be conducted, there are insufficient data to provide guidance on the preferred immunosuppressive agents or treatment regimen. 17 However, for a subset of 47 PRCA patients from England, France, and Germany who had virtually complete follow-up information, the European PRCA Study Group reported that hematologic recovery rates were highest with cyclophosphamide and corticosteroids (87%) and lowest with intravenous immune globulin (11%). Hematologic responsiveness was noted in these patients after a median of three months of immunosuppression (Table 3) . In Canada and Europe in 1999 and 2000, several patients diagnosed with epoetin-associated PRCA were empirically treated with renal transplantation after failing multiple immunosuppressive regimens. These individuals experienced rapid hematologic responses, after which policy makers in several countries made chronic kidney disease patients with epoetin-associated PRCA a higher priority on the waiting lists for renal transplantation procedures.
The European PRCA Study Group reported that the majority of the PRCA patients who achieved a hematologic recovery had anti-erythropoietin antibody levels below the lower limit of detection in the referral laboratory of one of the co-authors (NC). 17 For those PRCA patients who do not clear the anti-erythropoietin antibodies with immunosuppression alone, renal transplantation appears to be a viable treatment option.
Several epoetin-associated PRCA patients, after failing treatment with multiple immunosuppressive agents, developed a reticulocytosis one day after renal Geographic variations in PRCA treatment and outcomes exist. Six countries (Canada, France, England, Australia, Spain, and Switzerland) accounted for almost 70% of the cases we report. These countries had the highest rates of subcutaneous use of the human serum albumin-free formulation of Eprex  and the highest exposure-adjusted incidence rates. 3 Overall, Switzerland had the highest PRCA prevalence with one case per 460 epoetin-treated chronic kidney disease patients. 34 Spain had the lowest hematologic recovery rates and the highest rates of intravenous immunoglobulin use as immunosuppressive therapy, while all six of the Singapore PRCA patients recoveredfive of whom had received cyclosporin for immunosuppression. A published case series from Thailand described four epoetin-associated PRCA patients who failed immunosuppressive therapy initially, but recovered epoetin responsiveness shortly after undergoing renal transplantation. 19 These patients all displayed HLA DR B1*9, an allele present in 8.7% of the general Thai population. Considering the low incidence of epoetinassociated PRCA and the identification of HLA B1*9 in these patients, the authors speculated that there may be a role for major histocompatibility complex encoded proteins that relates to immune recognition and production of antibodies to recombinant epoetins. 19 This should be interpreted with caution, however, since there have been no further studies supporting this observation.
In the future, it is likely that few individuals will develop this serious syndrome. Two factors hypothesized to contribute to the development of anti-erythropoietin antibodies are the subcutaneous administration of the human-serum albumin-free formulation of Eprex ® and leachates from the rubber stopper of pre-filled syringes of this Eprex 3, 35 Co-injection of leachates and either epoetin alfa or ovalbumin results in increased antibody production in BDF-1 mice, demonstrating purportedly adjuvant activity of leachates. 35 In mid-2003, a Teflon coating was added to the rubber stopper of pre-filled syringes of human serum albumin-free Eprex ® . Subsequently, the exposureadjusted incidence rate decreased 13-fold when this product was administered intravenously to chronic kidney disease patients. 36 However, the relative impact of the Telflon ® -coating of the rubber stopper versus the change to intravenous administration is unclear. Of note, the formulation of the human serum albumin-free Eprex ® product has not changed since 1998.
The limitations of this study should be identified. First, the diagnosis of epoetinassociated PRCA should be based on results of clinical information, bone marrow examination and the demonstration of anti-erythropoietin antibodies (Table 1) . 22, 37 Presence of anti-erythropoietin antibodies has been assessed using several different methods which vary in sensitivity and specificity. 38 At referral labs in Europe, a first set of immunoglobulin assays (RIPA, ELISA, or surface plasmon resonance) are used to identify binding antibodies in patients who are being evaluated for suspected epoetinassociated PRCA. Then, an in vitro bioassay is used to identify the neutralizing ability of the antibodies. [38] [39] [40] [41] [42] [43] In the patients reported herein, antibodies were evaluated primarily by radioimmunoassay with only a minority of the case reports including information on neutralizing antibody assay results. Second, the majority of our cases were obtained from voluntary reports of variable quality, submitted by health professionals to government regulatory authorities. A systematic approach to obtain long-term follow-up information could not be pursued. 37 Moreover, median follow-up in this study was nine months and follow-up information after initial reporting of hematologic recovery was frequently not available. Due to the relatively limited follow-up periods in our database, mortalityrelated information could not be reported herein. In contrast, the European PRCA Study
Group prospectively obtained comprehensive clinical and laboratory information for many patients and were able to report findings on long-term clinical and laboratory information for 47 patients with epoetin-associated PRCA in France, England, and
Germany. 17 These patients were identified through collaboration of senior investigators in 
